T. Tamura

Publications520
h-index61
Citations18,158
Highly Influential Citations729
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • N. Saijo
  • 939 Publications • 36,223 Citations
  • N. Yamamoto
  • 476 Publications • 9,138 Citations
  • K. Nakagawa
  • 864 Publications • 36,884 Citations
  • Y. Ohe
  • 681 Publications • 23,363 Citations
  • Publications
  • Influence
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
TLDR
Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in patients with pretreated advanced non-small-cell lung cancer.
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.
TLDR
Irinotecan plus cisplatin is an effective treatment for metastatic small-cell lung cancer and severe or life-threatening diarrhea was more frequent in the irinotican-plus-cisplatin group than in the etoposide-plus -cis Platin group.
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.
  • T. Takano, Y. Ohe, T. Tamura
  • Medicine, Biology
    Journal of clinical oncology : official journal…
  • 1 October 2005
TLDR
EGFR mutations and increased copy numbers were significantly associated with better clinical outcome in gefitinib-treated NSCLC patients.
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology…
TLDR
This study strongly suggests that cisplatin plus etoposide and concurrent radiotherapy is more effective for the treatment of LS-SCLC than cisPlatin plus Etoposid and sequential radiotherapy.
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.
TLDR
Gefitinib significantly improved objective response rate and quality of life versus docetaxel; progression-free survival, disease control rates, and symptom improvement were similar for the two treatments.
Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer
TLDR
It is suggested that patients with EGFR mutations seem to have better outcomes with gefitinib treatment, in terms of progression-free survival, overall survival, and response, than those patients without EG FR mutations.
The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer
Programmed cell death ligand-1 (PD-L1) has recently gained considerable attention for its role in tumor immune escape. Here, we identify a miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant…
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.
TLDR
The addition of ipilimumab to first-line chemotherapy did not prolong OS compared with chemotherapy alone in patients with advanced squamous NSCLC and the safety profile was consistent with that observed in previous lung and melanoma studies.
...
1
2
3
4
5
...